Home » Topics » Disease categories and therapies » Respiratory

Respiratory
RSS

Takeda's PAF antagonist evaluated in preclinical model of asthma

Dec. 2, 1997

Dual-action compound YM-158 shows potential for asthma

Dec. 1, 1997

Preclinical results reported for Novartis' PDE IV inhibitor

Dec. 1, 1997

New antiasthma compound reported at Japanese congress

Dec. 1, 1997

European approvals for RPR's Nasacort AQ

Nov. 28, 1997

Bronchodilating mechanism of PDE IV inhibitors investigated using CP-80633

Nov. 27, 1997

Ono's elastase inhibitor poised to enter phase I in Europe

Nov. 27, 1997

Fujirebio, Nippon Chemiphar to codevelop antiasthma drug

Nov. 26, 1997

Arzneimittelwerk Dresden prepares new 5-LO inhibitors

Nov. 26, 1997

Dual CysLT1/H1 receptor antagonists described in patent literature

Nov. 25, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Elixirgen and Nippon Shinyaku sign EXG-7001 option agreement
BioWorld Science
Elixirgen Therapeutics Inc. has entered into an option agreement with Nippon Shinyaku Co. Ltd. for the development and commercialization of EXG-7001 for Duchenne...
Investors bet on transformative BCI tech for neuro disorders
BioWorld
An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....